Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory Bowel Diseases"
DOI: 10.1093/ibd/izy160
Abstract: Abstract Background Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). As a small molecule, tofacitinib is… read more here.
Keywords: tofacitinib; pregnancy; exposure tofacitinib; exposure ... See more keywords